The results of the TCGA study of thymic epithelial tumors (Table 1) confirmed previous studies that revealed absence of targetable mutations as tissue-based biomarkers in thymomas (reviewed in [1, 2]) and presence of only rare clinically meaningful mutations (e.g., of the KIT gene) in TCs [64]. The gene discussed is KIT; the disease is thymic epithelial neoplasm.